BioVie Inc. has reported a net loss of approximately $22.1 million for the fiscal year ending June 30, 2026, an increase from the $17.5 million loss recorded in the previous year. This increase is primarily attributed to a rise in operating expenses, which totaled around $22.7 million, compared to $18.1 million in the prior year. The increase in operating expenses was largely driven by a $4.7 million rise in research and development (R&D) costs, reflecting heightened activity in clinical trials for its lead product candidates, bezisterim (NE3107) and BIV201. The company has not generated any revenue to date, and its accumulated deficit has reached approximately $374.3 million.
In terms of strategic developments, BioVie has made significant progress in its clinical programs. The company recently completed a Phase 2b clinical trial for bezisterim in patients with Parkinson's disease, which successfully met its primary endpoints, demonstrating improvements in inflammatory biomarkers and clinical outcomes. Additionally, the company is advancing its Phase 2 ADDRESS-LC study for long COVID, with topline results expected in late summer 2026. BioVie has also received a $13.1 million grant from the U.S. Department of Defense to support this research.
Operationally, BioVie has maintained a lean workforce, with 13 full-time employees as of the latest reporting period. The company has focused on expanding its clinical trials, which have seen increased engagement and enrollment. The total cost incurred for the long COVID study was approximately $12.9 million, with the company recognizing grant reimbursements of $7.6 million for the year. The company’s cash and cash equivalents stood at approximately $9.0 million as of June 30, 2026, down from $17.5 million the previous year, indicating a need for additional capital to sustain operations.
Looking ahead, BioVie faces challenges in securing sufficient financing to continue its operations and clinical development efforts. The company has indicated that its future viability largely depends on its ability to raise additional capital through equity sales or other strategic transactions. Management has expressed uncertainty regarding the ability to obtain financing on favorable terms, which raises substantial doubt about the company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty, highlighting the critical need for ongoing funding to support its drug development initiatives.
About BIOVIE INC.
BioVie Inc. is a clinical-stage biopharmaceutical company developing innovative drug therapies targeting neurological and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases, long COVID, and advanced liver cirrhosis. Its key products include bezisterim, an oral anti-inflammatory agent addressing neuroinflammation and insulin resistance, and BIV201, a novel terlipressin formulation for liver disease complications. BioVie focuses on advancing clinical trials and leveraging proprietary formulations and intellectual property to address significant unmet medical needs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov